Verified Nov 2026
Other
·

London, England
·
Since 2018
Advanz Pharma is a London-based pharmaceutical company founded in 2018 (rebranded from Concordia Healthcare) with 500-1,000 employees and revenue between $500 million and $1 billion. It develops specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, gastroenterology, and oncology, operating in over 90 countries. The company has recently acquired global rights to the rare disease specialty brand Zavesca and partnered with Alvotech to commercialize additional biosimilars in Europe.
Advanz Pharma at a glance
Revenue
$500M-1B
Est. band
Employees
500-1,000
Founded
2018
Headquarters
London, England
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Advanz Pharma is a London-based pharmaceutical company founded in 2018 (rebranded from Concordia Healthcare) with 500-1,000 employees and revenue between $500 million and $1 billion. It develops specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, gastroenterology, and oncology, operating in over 90 countries. The company has recently acquired global rights to the rare disease specialty brand Zavesca and partnered with Alvotech to commercialize additional biosimilars in Europe.
At a glance
Attribute | Detail |
|---|---|
Founded | 2018 |
Headquarters | London, England |
Employees | 500-1,000 |
Revenue | $500M-1B (estimated) |
What Advanz Pharma makes
The company offers a diverse portfolio spanning medicines, specialty generics, biosimilars, and originator brands, with a focus on acquiring and commercializing legacy pharmaceutical compounds to serve wholesalers, distributors, hospitals, and pharmacies.
Latest developments
2026-10-14 — Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg | ADVANZ PHARMA (advanzpharma.com)
2025-12-18 — ADVANZ PHARMA Acquires Territory Rights to Progynova® and Cyclo-Progynova® in Selected Countries in EMEA and Global Rights to Ilomedin® | ADVANZ PHARMA (advanzpharma.com)
2025-10-13 — ADVANZ PHARMA Acquires Global Rights to Rare Disease Specialty Brand Zavesca® | ADVANZ PHARMA (advanzpharma.com)
2025-06-18 — ADVANZ PHARMA acquires Testoviron® rights from Bayer in Europe and parts of LATAM, MEA, and APAC | ADVANZ PHARMA (advanzpharma.com)
2025-05-28 — Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe | ADVANZ PHARMA (advanzpharma.com)
2025-05-15 — ADVANZ PHARMA and PHARMATHEN Expand Strategic Partnership with Exclusive License and Supply Agreement | ADVANZ PHARMA (advanzpharma.com)
Company details
Advanz Pharma operates through subsidiaries including Boucher & Muir Pty Ltd serving the Australia, New Zealand, and South Pacific markets, and has secured over $1.17 billion in funding since its founding. Advanz Pharma was founded in 2018, has an estimated 500-1,000 employees, and is headquartered in London, England.
Frequently asked questions
What does Advanz Pharma do?
Advanz Pharma is a London-based pharmaceutical company founded in 2018 (rebranded from Concordia Healthcare) with 500-1,000 employees and revenue between $500 million and $1 billion. It develops specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, gastroenterology, and oncology, operating in over 90 countries. The company has recently acquired global rights to the rare disease specialty brand Zavesca and partnered with Alvotech to commercialize additional biosimilars in Europe.
Where is Advanz Pharma headquartered?
Advanz Pharma is headquartered in London, England.
When was Advanz Pharma founded?
Advanz Pharma was founded in 2018.
How big is Advanz Pharma?
Advanz Pharma has an estimated 500-1,000 employees, with revenue in the $500M-1B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
